Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 1991;11:816-826

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saito, Y.
Right arrow Articles by Goto, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saito, Y.
Right arrow Articles by Goto, Y.

Arteriosclerosis and Thrombosis, Vol 11, 816-826, Copyright © 1991 by American Heart Association

ARTICLES

Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study

Y Saito, S Yoshida, N Nakaya, Y Hata and Y Goto
Second Department of Internal Medicine, University of Chiba School of Medicine, Japan.

Previous studies have shown that simvastatin, a hydroxymethyl glutaryl coenzyme A reductase inhibitor, reduces plasma cholesterol levels when administered once a day. In the present study, the efficacy and tolerability of a morning and an evening dose were compared. The dosages employed were 2.5 and 5 mg for 12 weeks. This investigation was a double-blind, placebo-controlled study involving 172 hyperlipidemic subjects whose plasma cholesterol levels were higher than 220 mg/dl. During the study period, mean changes in plasma cholesterol level (from baseline) were -11% with the 2.5-mg q.a.m. regimen, -15% with the 2.5- mg q.p.m. regimen, -14% with the 5-mg q.a.m. regimen, and -21% with the 5-mg q.p.m. regimen. Each of these changes was statistically significant when compared with that in the placebo group (p less than 0.001). In addition, the reduction in cholesterol level was significantly greater with the evening regimen than with the morning regimen for both the 2.5-mg (p less than 0.05) and the 5-mg (p less than 0.05) dosages. The changes in triglyceride and high density lipoprotein cholesterol levels in each group were not significantly different from those in the placebo group. There were no differences in the incidence of clinical adverse reactions among the various treatment groups. In conclusion, when simvastatin was administered orally once per day in the evening, it reduced cholesterol levels to a significantly greater degree than when it was given in the morning.


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
R. Plakogiannis and H. Cohen
Optimal Low-Density Lipoprotein Cholesterol Lowering-- Morning Versus Evening Statin Administration
Ann. Pharmacother., January 1, 2007; 41(1): 106 - 110.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
R. Plakogiannis, H. Cohen, and D. Taft
Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia
Am. J. Health Syst. Pharm., December 1, 2005; 62(23): 2491 - 2494.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
A. Wallace, D. Chinn, and G. Rubin
Taking simvastatin in the morning compared with in the evening: randomised controlled trial
BMJ, October 4, 2003; 327(7418): 788 - 788.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
G.R. Thompson, F. O'Neill, and M. Seed
Why some patients respond poorly to statins and how this might be remedied
Eur. Heart J., February 1, 2002; 23(3): 200 - 206.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
D. R. Illingworth, E. A. Stein, Y. B. Mitchel, C. A. Dujovne, P. H. Frost, R. H. Knopp, P. Tun, R. V. Zupkis, and R. A. Greguski
Comparative Effects of Lovastatin and Niacin in Primary Hypercholesterolemia: A Prospective Trial
Arch Intern Med, July 25, 1994; 154(14): 1586 - 1595.
[Abstract] [PDF]


ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1991 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.